|Dr. Mark Burnham Smith Ph.D.||CEO & Director||698.66k||N/A||1987|
|Mr. Marc B. Blaustein C.F.A., CFA, MPP||COO, Principal Financial & Accounting Officer||378.21k||N/A||1963|
|Mr. Joseph D. Vittiglio Esq., J.D.||Chief Bus. & Legal Officer and Corp. Sec.||526.08k||N/A||1972|
|Mr. Bryan Gillis M.B.A.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. James S. Sigler||Exec. VP of CMC||N/A||N/A||1961|
|Ms. Sonia Timberlake||Sr. VP of Research||N/A||N/A||N/A|
|Dr. Howard Franklin M.B.A., M.D.||Interim Chief Medical Officer||N/A||N/A||N/A|
|Dr. Alka Batycky Ph.D.||Chief Devel. Officer||N/A||N/A||N/A|
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Finch Therapeutics Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.